 Connection
Ruud Dings to Cell Line, Tumor
This is a "connection" page, showing publications Ruud Dings has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.799 |
|
|
|
-
Jenkins SV, Shah S, Jamshidi-Parsian A, Mortazavi A, Kristian H, Boysen G, Vang KB, Griffin RJ, Rajaram N, Dings RPM. Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance. Radiat Res. 2024 02 01; 201(2):174-187.
Score: 0.166
-
Koonce NA, Griffin RJ, Dings RPM. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models. Int J Mol Sci. 2017 Dec 09; 18(12).
Score: 0.108
-
Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther. 2013 Mar; 344(3):589-99.
Score: 0.077
-
Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem. 2012 Jun 14; 55(11):5121-9.
Score: 0.074
-
Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett. 2008 Jul 08; 265(2):270-80.
Score: 0.055
-
Jamshidi-Parsian A, Jenkins SV, Tran A, Bragg A, Davis R, Griffin C, Siegel E, Dings RPM, Griffin RJ, Boysen G. CB-839 induces reversible dormancy in lung tumor-cells. Eur J Pharmacol. 2024 Nov 05; 982:176912.
Score: 0.043
-
Johnsrud AJ, Jenkins SV, Jamshidi-Parsian A, Quick CM, Galhardo EP, Dings RPM, Vang KB, Narayanasamy G, Makhoul I, Griffin RJ. Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiat Res. 2020 12 01; 194(6):688-697.
Score: 0.033
-
Dadgar S, Troncoso JR, Siegel ER, Curry NM, Griffin RJ, Dings RPM, Rajaram N. Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. Neoplasia. 2021 01; 23(1):49-57.
Score: 0.033
-
Jenkins SV, Nedosekin DA, Shaulis BJ, Wang T, Jamshidi-Parsian A, Pollock ED, Chen J, Dings RPM, Griffin RJ. Enhanced Photothermal Treatment Efficacy and Normal Tissue Protection via Vascular Targeted Gold Nanocages. Nanotheranostics. 2019; 3(2):145-155.
Score: 0.030
-
Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Simecka CM, Kore RA, Dings RPM, Griffin RJ. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol. 2019 04; 95(4):436-442.
Score: 0.029
-
Koonce NA, Juratli MA, Cai C, Sarimollaoglu M, Menyaev YA, Dent J, Quick CM, Dings RPM, Nedosekin D, Zharov V, Griffin RJ. Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in?vivo flow cytometry. Biochem Biophys Res Commun. 2017 10 21; 492(3):507-512.
Score: 0.026
-
Alhallak K, Jenkins SV, Lee DE, Greene NP, Quinn KP, Griffin RJ, Dings RPM, Rajaram N. Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells. J Biomed Opt. 2017 06 01; 22(6):60502.
Score: 0.026
-
Koonce NA, Levy J, Hardee ME, Jamshidi-Parsian A, Vang KB, Sharma S, Raleigh JA, Dings RP, Griffin RJ. Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. PLoS One. 2015; 10(8):e0135607.
Score: 0.023
-
L?ppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Gr?ll H. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation. Eur J Med Chem. 2015 Jan 07; 89:279-95.
Score: 0.022
-
Griffin RJ, Koonce NA, Dings RP, Siegel E, Moros EG, Br?uer-Krisch E, Corry PM. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide. Radiat Res. 2012 Jun; 177(6):804-12.
Score: 0.018
-
Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun. 2006 Oct 27; 349(3):1073-8.
Score: 0.012
-
Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006 Apr; 20(6):621-30.
Score: 0.012
-
Mayo KH, Dings RP, Flader C, Nesmelova I, Hargittai B, van der Schaft DW, van Eijk LI, Walek D, Haseman J, Hoye TR, Griffioen AW. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J Biol Chem. 2003 Nov 14; 278(46):45746-52.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|